NCT06663943 - A Randomized Study on Pemphigus Treatment With Humanized CD38 Antibody CM313. | Biotech Hunter

Enrollment

100

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 30, 2026

Study Completion Date

November 1, 2026

Conditions

Pemphigus DiseasePemphigus Vulgaris (PV)

Interventions

DRUG

CM313 (SC)

CM313 is an anti-CD38 monoclonal antibody that can help pemphigus patients systematically treat rapid glucocorticoid reduction. It has been proven to have good safety in non-clinical studies and is suitable for human studies

DRUG

Glucocorticoids

Patients in the control group receive azathioprine in combination with steroid therapy.